Covid-19 Update

Mike Amesbury Excerpts

Monday 17th May 2021 Commons Chamber

[Matt Hancock]

My hon. Friend will no doubt have seen the note that went out last week from Dr Nikki Kanani about ensuring that face-to-face access is available to the appropriate clinician, and that the use of technology should be encouraged but should be a matter for a discussion between the clinician and the patient. For many people, it is more of an advantage. Personally, I use telemedicine, and it is much more convenient for me, as a healthy and busy 42-year-old, but for some people it is right to see their clinician face to face. That letter went out last week, and we obviously constantly keep this issue under review and monitor it carefully.

[Mike Amesbury (Weaver Vale) (Lab)]

Last week, I met the Taskforce for Lung Health, which raised a concern about an increased occurrence of lung scarring in long covid sufferers. What assessment has the Secretary of State made of the impact of this on potential resources for the health service?

[Matt Hancock]

We are of course worried about the impact of long covid, and the evidence is growing about the different impacts. The clinical advice is that there are a number of different syndromes that are, together, badged as long covid. For some people it has an impact, as the hon. Member says, on lung scarring; for some people the impact is more neurological. So we have to make sure that the services, the response and, indeed, the research are targeted at the different types of long covid. I am very happy to arrange a discussion between him and our clinical leaders on long covid, because it is a very important topic.